Funding opportunity

Funding opportunity: Pre-announcement: international collaboration to address antimicrobial resistance

Apply for funding to develop or improve drugs or plant protection agents to help:

  • treat bacterial or fungal infections
  • reduce the spread of resistance to drugs.

You should:

  • be based at a research organisation eligible for MRC funding
  • apply as part of a consortium of transnational partners.

Your project should involve either:

  • licensed antibiotics or antifungals
  • agents in pre-clinical or early clinical development.

It could aim to:

  • improve efficacy or specificity
  • repurpose existing interventions
  • optimise combinations of drugs or plant protection agents
  • design and implement:
    • new strategies
    • innovative tools, including novel chemistry and new materials.

This is a pre-announcement for the ‘Disrupting drug Resistance Using Innovative Design’ (DRUID) funding opportunity. This guidance gives all the information available so far.

The full details and application process will be available on the JPIAMR website.

UK-based researchers will also need to submit a UK budget to UKRI.

We will update this guidance with details of how to do this by the opening date.

Who can apply

Standard MRC eligibility applies.

You should be based at a research organisation eligible for MRC funding.

You must apply as part of a consortium of transnational partners.

What we're looking for

This is the fourteenth JPIAMR joint transnational research funding opportunity, named DRUID.

DRUID aims to improve:

  • treatment of bacterial and fungal infections (including co-infection)
  • prevention of the emergence or spread of resistance in humans, animals or plants.

How to apply

The opportunity opens on 11 January 2022. More details will be made available on this page.

Contact details

Ask about this funding opportunity

Email: amr@mrc.ukri.org

NOTE Council web content is being transitioned to this website – let us know if you have feedback or would like to help us test new developments.